KIYATEC is ushering in a new world of cancer diagnostics that
use living cells grown and tested in a more relevant 3D environment.

Clinical Cancer Diagnostics

Cancer DxKIYATEC is driving the future of clinical cancer diagnostics to provide more accurate prediction of patient-specific response to cancer treatments.  Placing the patient's own living cancer cells into a more biologically relevant 3D culture environment, KIYATEC cell-based assays can better assist oncologists with improved response data and faster turnaround!

Read More

Preclinical Services & Partnering

3DTMEKIYATEC 3D cell-based models provide a physiologically relevant, cost-effective platform for late-stage phenotypic preclinical testing of small molecules and biologics to answer important questions regarding toxicity and efficacy. Opportunities also exist for co-clinical trial partnering to apply ex vivo patient selection based on cell response.

Read More


KIYATEC awarded AdvaMed Emerging Growth Company presentation and scholarship
Read More

KIYATEC recognized with spot in NIH "Innovation Zone" at BIO 2014
Read More

KIYATEC appoints Bob Silverman as Board Chairman
Read More

KIYATEC awarded National Cancer Institute contract to establish 3D breast cancer model
Read More


DARPA / NIH Microphysiological Systems Meeting
Arlington, VA
Aug 6-7


AdvaMed 2014
Emerging Growth Company Presentation
Chicago, IL
Oct 6-8